New clinical trial research presented at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer suggests that ARMO BioSciences’ immuno-oncology drug, AM0010, is effective in treating patients with advanced pancreatic cancer.
New clinical trial research presented at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer suggests that ARMO BioSciences’ immuno-oncology drug, AM0010, is effective in treating patients with advanced pancreatic cancer.
The phase 1/1b trial included 47 advanced pancreatic ductal adenocarcinoma (PDAC) patients. Of the total patients, 22 were treated with AM0010 alone, while 21 patients were given AM0010 in combination with FOLFOX chemotherapy. Both forms of treatment were observed to be effective; however, grade 3/4 treatment of daily doses of AM0010 correlated with thrombocytopenia, anemia, and neutropenia. When AM0010 was utilized with FOLFOX and on a modified dose schedule, no grade 3/4 adverse events were experienced.
“In an ongoing phase 1/1b clinical trial, AM0010 in combination with FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin) chemotherapy has demonstrated extremely promising efficacy and safety data to date in patients with advanced pancreatic cancer,” J. Randolph Hecht, MD, professor of clinical medicine at the David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California and an investigator for the phase 3 clinical trial, said in a statement. “The median follow-up on this study is 14.2 months (range 6.8-18.9 months) and 10 of 21 patients (47%) are still alive after more than one year.”
The phase 3 clinical trial will include the modified dose schedule, of 5 days on and 2 days off, of AM0010 and FOLFOX combination treatment in patients with advanced pancreatic cancer. The increased immune stimulatory cytokines and the increase of T cell clones resulting from AM0010 and FOLFOX combination treatment is associated with an overall increased survival of PDAC patients.
“We are very encouraged that we continue to see such promising data trends from the patients in this trial,” said Peter Van Vlasselaer, PhD, founder of ARMO. “These phase 1/1b data provide the rationale for our ongoing pivotal phase 3 clinical trial of AM0010 in combination with FOLFOX as second-line therapy for advanced metastatic pancreatic cancer.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More